Celgene To Pay $55M Over Cancer Drug Monopoly Claims
Celgene Corp. on Wednesday agreed to cut a check for $55 million to end a proposed class action alleging a sweeping scheme to monopolize the market for two cancer drugs that...To view the full article, register now.
Already a subscriber? Click here to view full article